SCHA vs. ISCB Comes Down to Sector Tilt and Your Drawdown Tolerance

SCHA and ISCB both charge a 0.04% expense ratio, but SCHA is far larger at $22.0 billion in AUM versus ISCB’s $268.5 million and also has higher recent liquidity. SCHA led on 1-year total return at 47.1% versus 38.4% for ISCB, while ISCB offered a slightly higher 1.3% dividend yield and a marginally smaller 5-year max drawdown of -29.94% versus -30.78%. The main distinction is portfolio tilt: SCHA leans more toward Technology, while ISCB has greater Healthcare exposure.

Analysis

The practical edge here is not in the wrapper economics; both vehicles are too cheap for fees to matter, so the trade is really about factor composition and implementation quality. SCHA’s larger asset base and tighter liquidity make it the cleaner instrument for expressing a small-cap beta view in size, while ISCB’s lower AUM means wider spreads and higher market-impact costs can quietly erase its slight yield advantage for anyone trading frequently. That makes ISCB more of a strategic hold than a tactical vehicle.

The sector tilt matters more than the headline return differential. SCHA’s heavier Technology exposure makes it more vulnerable if small-cap leadership broadens away from long-duration growth and toward cyclicals/defensives, while ISCB’s Healthcare and Industrials mix should hold up better in an environment where rates stay higher-for-longer and market participants rotate toward balance-sheet quality. In other words, ISCB is the more “rate-resilient” small-cap sleeve; SCHA is the more momentum-sensitive one.

The underlying holdings also flag a second-order risk: both funds share meaningful exposure to names like LITE and RVMD, so stock-specific disappointment in a few higher-beta small-cap winners can hit both products simultaneously. That overlap means the supposed diversification benefit of owning both is lower than it looks, especially in a risk-off tape where factor correlations jump toward one. The small difference in max drawdown is not enough to justify paying any liquidity penalty for ISCB unless an investor explicitly wants the sector tilt.

Contrarian view: consensus is overweighting the recent 1-year outperformance of SCHA as if it were durable evidence of superiority, when it may simply be the market rewarding a more growth-sensitive basket during a favorable risk regime. If small-cap breadth improves and investors start demanding earnings visibility over duration, the relative return gap could narrow fast, and ISCB’s composition may prove the more defensive way to own the asset class.

Key Decisions for Investors

• For new small-cap exposure, use SCHA as the default execution vehicle over the next 1-3 months: better liquidity, lower implementation friction, and easier scaling for institutional tickets; downside is that it will underperform if the market rotates hard into Healthcare/Industrials.
• If the portfolio is already tech-heavy, allocate incremental small-cap capital to ISCB over the next quarter as a factor hedge; the expected payoff is modest relative outperformance in a higher-rate / lower-duration regime, with the main risk being spread and liquidity drag.
• Pair trade: long ISCB / short SCHA for a 3-6 month sector-rotation expression if rates remain sticky and breadth improves. Risk/reward is attractive if Tech underperforms and Healthcare/Industrials gain leadership, but stop out if growth momentum reaccelerates.
• Avoid owning both ETFs unless there is a specific tax or rebalancing reason; the holding overlap reduces diversification benefit. Use one core sleeve and add single-name tilts elsewhere to avoid double-paying for the same factor exposure.
• Monitor relative performance on a 6-8 week basis: if SCHA keeps outperforming despite rising rates or weakening breadth, it likely signals persistent speculative appetite and the pair trade should be covered.